SHELTON, Conn., Oct. 17, 2017 /PRNewswire/ -- NanoViricides,
Inc. (NYSE American: NNVC) (the "Company") will present the results
of its anti-herpes nanoviricide treatment for Viral Acute Retinal
Necrosis (vARN) at the 2017 Annual meeting of the Ocular
Microbiology and Immunology Group (OMIG) of the American Academy of
Ophthalmology to be held in New Orleans,
LA.
v-ARN is a disease of the retina of the eye caused by various
herpes viruses that leads to severe loss of vision and
blindness. The infecting agent in this study was herpes
simplex virus-2 (HSV-2), the type of herpes virus that also causes
genital herpes.
The abstract of the study has been accepted for presentation at
this OMIG meeting on November
10th, 2017. Dr. Vivien Boniuk, consultant in ophthalmology at
NanoViricides, Inc. will make the scientific presentation.
The presentation will cover both the inhibition of virus infection
and prevention of ocular tissue damage following virus
infection.
Viral Acute Retinal Necrosis is characterized by severe ocular
inflammation, retinal necrosis, and a high incidence of retinal
detachment (RD) leading to visual loss and blindness. This
disease is caused by members of the herpesvirus family, including,
herpes simplex virus-2 (HSV-2), varicella zoster virus (VZV), and
herpes simplex virus (HSV-1). An estimated 50,000 new and
recurrent cases of viral ARN per year are reported in the United States alone.
The study was performed in the laboratory of Professor
Curtis Brandt, Collaborative
Ophthalmic Research Laboratories, CORL, at the University of Wisconsin. Dr. Brandt is Professor in
the Departments of Ophthalmology and Visual Sciences, Medical
Microbiology and Immunology, and Director of the Vision Research
Core at the University of
Wisconsin.
NanoViricides believes that its broad-spectrum anti-herpes drug
candidates being developed in its HerpeCide™ program may be capable
of attacking many different herpesviruses. The Company
intends to maximize shareholder value from this asset by
aggressively expanding its portfolio of herpesvirus indications.
The Company is already developing drugs for at least four different
indications based on these broad-spectrum anti-herpes drug
candidates, namely: (i) skin cream for the treatment of shingles
(VZV), (ii) skin cream for the treatment of herpes labialis
(HSV-1), (iii) eye drops for the treatment of herpes keratitis, a
disease of the external eye (HSV-1), and (iv) skin cream for the
treatment of genital herpes (HSV-2). Successful studies on vARN
would add a fifth indication to this growing portfolio, further
expanding the potential market.
About NanoViricides:
NanoViricides, Inc. (www.nanoviricides.com) is a development stage
company that is creating special purpose nanomaterials for
antiviral therapy. The Company's novel nanoviricide® class of drug
candidates are designed to specifically attack enveloped virus
particles and to dismantle them. The Company is developing drugs
against a number of viral diseases including VZV, oral and genital
Herpes, viral diseases of the eye including EKC and herpes
keratitis, H1N1 swine flu, H5N1 bird flu, seasonal Influenza, HIV,
Hepatitis C, Rabies, Dengue fever, and Ebola virus, among
others.
About CORL:
CORL is a collaborative team of internationally recognized vision
scientists founded on providing world-class vision research support
for industry at the University of
Wisconsin. CORL understands industry's timeline-driven
culture and can collaborate with industry via fee-for-service
agreements.
This press release contains forward-looking statements that
reflect the Company's current expectation regarding future events.
Actual events could differ materially and substantially from those
projected herein and depend on a number of factors. Certain
statements in this release, and other written or oral statements
made by NanoViricides, Inc. are "forward-looking statements" within
the meaning of Section 27A of the Securities Act of 1933 and
Section 21E of the Securities Exchange Act of 1934. You should not
place undue reliance on forward-looking statements since they
involve known and unknown risks, uncertainties and other factors
which are, in some cases, beyond the Company's control and which
could, and likely will, materially affect actual results, levels of
activity, performance or achievements. The Company assumes no
obligation to publicly update or revise these forward-looking
statements for any reason, or to update the reasons actual results
could differ materially from those anticipated in these
forward-looking statements, even if new information becomes
available in the future. Important factors that could cause actual
results to differ materially from the company's expectations
include, but are not limited to, those factors that are disclosed
under the heading "Risk Factors" and elsewhere in documents filed
by the company from time to time with the United States Securities
and Exchange Commission and other regulatory authorities.
Although it is not possible to predict or identify all such
factors, they may include the following: demonstration and proof of
principle in pre-clinical trials that a nanoviricide is safe and
effective; successful development of our product candidates; our
ability to seek and obtain regulatory approvals, including with
respect to the indications we are seeking; the successful
commercialization of our product candidates; and market acceptance
of our products.
View original content with
multimedia:http://www.prnewswire.com/news-releases/nanoviricides-to-present-results-on-successful-treatment-of-herpes-induced-acute-retinal-necrosis-at-the-annual-meeting-of-the-ocular-microbiology-and-immunology-group-omig-of-the-american-academy-of-ophthalmology-300537756.html
SOURCE NanoViricides, Inc.